Abstract
An analysis of benzenoid substitution patterns in small molecule active
pharmaceutical ingredients (APIs) approved by the FDA reveals a preference for
1,4-substituted (para), 1-substituted
(mono), 1,2,4-substituted, and
1,2-substituted (ortho) arenes. Notably,
these substitution patterns are widely commercially available and readily
accessible by electrophilic aromatic substitution (SEAr), but more
highly substituted and contra-electronic substitution patterns are severely
underrepresented in drug substances. Finally, structural variation decreases
with increasing substitution and there is a strong reliance on natural product
scaffolds in drugs with more highly substituted benzenoid rings.